Results 251 to 260 of about 1,538,508 (356)

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

The Medicinal Chemistry at the “Polo de Xistoquímica” of the IQ‐UFRJ

, 2009
Joaquim F.M. Silva, Biank T. Gonçalves, Gizelda de O. D. Estrada, Ricardo S. Yaunner, Lucas Villas Bôas Hoelz   +4 more
openalex   +1 more source

The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria. [PDF]

Angew Chem Int Ed Engl
Woodland JG, Coertzen D, Wicht KJ, Hidalgo VF, Pasaje CFA, Godoy LC, Qahash T, Mmonwa MM, Dziwornu GA, Wambua L, Harries S, Korkor CM, Njoroge M, Krugmann L, Taylor D, Leshabane M, Langeveld H, Rabie T, Reader J, van der Watt M, Venter N, Erlank E, Aswat AS, Koekemoer LL, Yeo T, Jeon JH, Fidock DA, Gamo FJ, Wittlin S, Niles JC, Llinas M, Coulson LB, Birkholtz LM, Chibale K.   +33 more
europepmc   +1 more source

Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies

Molecular Oncology, EarlyView.
We investigated whether hypomethylating agents (HMAs) used in myeloid malignancies induce somatic retrotransposition. Our findings indicate that HMA treatment increases L1‐encoded protein expression but does not lead to detectable de novo retrotransposition events in either patient samples or cell lines.
Šárka Pavlová, Hana Svozilová, Marcela Krzyžánková, Radim Sonnek, Anastasiya Volakhava, Anastasia Smirnova, Tatiana Grigoreva, Zuzana Jašková, Hana Synáčková, Dennis Wahl, Michaela Bilčíková, Libor Červinek, Šárka Pospíšilová, Ilgar Mamedov, Karla Plevová   +14 more
wiley   +1 more source

Synthetic Approaches, Properties, and Applications of Acylals in Preparative and Medicinal Chemistry. [PDF]

Molecules
Keydel T, Link A.
europepmc   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective. [PDF]

RSC Med Chem
Prajapati V, Singh AK, Kumar A, Singh H, Pathak P, Grishina M, Kumar V, Khalilullah H, Verma A, Kumar P.   +9 more
europepmc   +1 more source

SensRORing cholesterol to drive protumoral myelopoiesis

Molecular Oncology, EarlyView.
Bleve et al. uncover a cholesterol‐driven immune evasion pathway, where RORγ‐dependent myelopoiesis shapes tumor immunosuppression. Targeting RORγ and PCSK9 emerges as a strategy to boost cancer immunotherapy. Protumoral myelopoiesis is a determinant of immunoevasion and tumor spread in many malignancies.
Sara Gennari, Luigi Nezi, Teresa Manzo
wiley   +1 more source

Syntheses and medicinal chemistry of spiro heterocyclic steroids. [PDF]

Beilstein J Org Chem
Romero-Hernández LL, Ahuja-Casarín AI, Merino-Montiel P, Montiel-Smith S, Vega-Báez JL, Sandoval-Ramírez J.   +5 more
europepmc   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source